- Report of Foreign Issuer (6-K)
30 6월 2009 - 9:28PM
Edgar (US Regulatory)
CONFORMED COPY
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1933
June 30, 2009
Pharmaxis Ltd
2/10 Rodborough Road,
Frenchs Forest, NSW 2086
Australia
(Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or
Form 40-F.)
Form 20-F
þ
Form 40-F
o
(Indicate by check mark whether the registrant by furnishing the information contained in this form
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.)
Yes
o
No
þ
(If Yes is marked, indicate below the file number assigned to the registrant in connection with
Rule 12g3-2(b):
82-
.)
|
|
|
|
|
|
ASX/Nasdaq Media Release
|
|
30 June 2009
|
Pharmaxis Closes Share Purchase Plan
Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced it had raised A$7.2 million from its Share
Purchase Plan which closed on 24 June 2009. Shareholders of the company were given the opportunity
to purchase up to $5,000 worth of shares each at the $2.35 price paid by institutional investors in
the recent placement.
A total of 1,584 shareholders participated in the plan under which the company will issue
approximately 3 million new shares and receive funds of approximately $7.2 million.
Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, We are very encouraged and
appreciative of the level of support from our shareholders. The total proceeds of the placement
and share purchase plan of $54 million puts us in a strong position from which to take our products
to the global markets.
Shares will be issued today, 30 June 2009, and are expected to be listed on the Australian
Securities Exchange on 2 July 2009. Holding statements will be posted on or about 1 July 2009.
#ends#
SOURCE:
Pharmaxis Ltd, Sydney, Australia
CONTACT:
Alan Robertson Chief Executive Officer
Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au
RELEASED THROUGH:
Australia:
Felicity Moffatt, phone +61 418 677 701 or email
felicity.moffatt@pharmaxis.com.au
United States:
Brandon Lewis, Trout Group, phone +1 646 378 2915 or email
blewis@troutgroup.com
Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this media release include statements regarding our expectations,
beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the
potential for Aridol and/or Bronchitol. All forward-looking statements included in this media
release are based upon information available to us as of the date hereof, and we assume no
obligation to update any such forward-looking statement as a result of new information, future
events or otherwise. We can not guarantee that any product candidate will receive FDA or other
regulatory approval or that we will seek any such approval. Factors that could cause or contribute
to such differences include, but are not limited to, factors discussed in the Risk Factors and
Other Uncertainties section of our Form 20-F lodged with the U.S. Securities and Exchange
Commission.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
Pharmaxis Ltd
(Registrant)
|
|
Date: June 30, 2009
|
By:
|
/s/ David McGarvey
|
|
|
|
Name:
|
David McGarvey
|
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024